Innovation Pharmaceuticals Inc (IPIX)

[thefamilyman]

You said, “Yes, the Polymedix trial had the bigger side effect problem, but being forced to repeatedly reduce the dosing all the way down to 1 day is not something you like to see.”

Actually, a single dose therapy would be the preferred therapy. The problem with Dapto’s 7 day regimen is that a significant amount of patients begin to feel better after a few days and then do not show up to get the remaining doses. That leaves the strongest bacteria alive to reproduce, eventually developing resistance to the drug. A single dose that does the job means you avoid that problem as well as the additional costs of multiple IV infusions in a medical setting.

You also said, “They said the efficacy using 1 day dosing was still comparable to daptomycin's, but you obviously want the ability to dose longer if needed.”

The 3 day dosing option from the Phase 2B is still a possibility if needed. Relax, if it beats the low bar set by Remdesivir, we all win whether we own IPIX stock or not.